

# ***Fibrinogen replacement therapy in acquired perioperative bleeding***

Sibylle Kietaihl

in collaboration with

Arash Afshari, Aamer B. Ahmed, Daniel Bolliger,  
Rachel Collis, Anne-Sophie Ducloy-Bouthors,  
Susan M. Goobie, Thorsten Haas, Marcus D. Lancé,  
Barto Nascimento, Vojislava Neskovic,  
Marco Ranucci, Christoph J. Schlimp,  
Kenichi A. Tanaka, Anne Juul Wikkelsø



# **Fibrinogen replacement therapy in acquired perioperative bleeding**



**UNI-MED Verlag AG**  
**Bremen - London - Boston**

**Kietaibl, Sibylle:**

Fibrinogen replacement therapy in acquired perioperative bleeding/Sibylle Kietaibl.-

1<sup>st</sup> edition - Bremen: UNI-MED, 2018 (UNI-MED SCIENCE)

ISBN 978-3-8374-6392-7

© 2018 by UNI-MED Verlag AG, D-28323 Bremen,  
International Medical Publishers (London, Boston)  
Internet: [www.uni-med.de](http://www.uni-med.de), e-mail: [info@uni-med.de](mailto:info@uni-med.de)

Printed in Europe

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way and storage in data banks. Violations are liable for prosecution under the German Copyright Law.

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publishers cannot guarantee the accuracy of any information about the application of operative techniques and medications contained in this book. In every individual case the user must check such information by consulting the relevant literature.

## ***MEDICINE - STATE OF THE ART***

---

UNI-MED Verlag AG, one of the leading medical publishing companies in Germany, presents its highly successful series of scientific textbooks, covering all medical subjects. The authors are specialists in their fields and present the topics precisely, comprehensively, and with the facility of quick reference in mind. The books will be most useful for all doctors who wish to keep up to date with the latest developments in medicine.

## ***Preface and acknowledgements***

---

Fibrinogen is a crucial molecule in humans with an extraordinary role in stopping and preventing bleeding: it is the substrate of clots. Fibrin networks in robust clots protect mankind against main causes of death in young age groups – maternal death due to peripartum haemorrhage (PPH) and exsanguination due to trauma-induced coagulopathy (TIC). Fibrinogen secures patient outcome during and after major surgical procedures in all age groups from neonates to frail elderly.

Fibrinogen is our coagulation factor No.1 – it would be worthwhile to declaring at least one calendar day as “fibrinogen day”. As a substitute, this book is dedicated to fibrinogen!

Internationally accepted experts donated their time gratuitously and shared their expertise and knowledge in their respective book chapters. As the initiator of our successful book project I express my gratitude to you, dear collaborators. My thanks also go to Dr. Wulfmeyer, editor of UNI-MED, for his professional support of our fibrinogen book coup. Last, but not least my thanks go to you, dear readers, for your interest. I hope that our compilation of fibrinogen replacement will allay your curiosity and thirst for knowledge.

*Vienna, June 2018*

*Sibylle Kietaihl*

# Authors

---

Arash Afshari, M.D., Ph.D.,  
Head of Research  
Department of Pediatric and Obstetric Anesthesia  
Juliane Marie Center  
Rigshospitalet  
University of Copenhagen  
Blegdamsvej 9  
DK-2100 Copenhagen  
Denmark

*Chapter 10.*

Aamer B. Ahmed, MD FRCA FACC FESC  
Department of Anaesthesia  
Glenfield Hospital, University Hospitals of Leicester NHS Trust  
Groby Road  
Leicester LE9 2ER  
United Kingdom

*Chapter 8.*

Daniel Bolliger, MD  
Department for Anesthesia  
Surgical Intensive Care, Prehospital Emergency Medicine and Pain Therapy  
Basel University Hospital  
Spitalstrasse 21  
CH-4031 Basel  
Switzerland  
Email: Daniel.Bolliger@usb.ch

*Chapter 2.*

Rachel Collis  
Department of Anaesthetics and Pain Control  
Cardiff & Vale University Health Board  
Cardiff  
UK  
Email: Rachel.Collis@wales.nhs.uk

*Chapter 5.*

Anne-Sophie Ducloy-Bouthors  
Pole anesthésie-réanimation  
Maternité Jeanne de Flandre, Academic Hospital  
Avenue Oscar Lambret  
59037 Lille  
France  
Email: anne-sophie.bouthors@chru-lille.fr

*Chapter 5.*

Susan M. Goobie, MD, FRCPC  
Associate Professor of Anaesthesiology  
Harvard Medical School Associate in Perioperative Anesthesia  
Clinical Director, Pharmacokinetics Laboratory  
Dept. of Anesthesiology, Critical Care & Pain Medicine  
300 Longwood Ave, Boston Children's Hospital  
Boston, MA 02115  
USA  
Email: Susan.Goobie@childrens.harvard.edu  
*Chapter 6.*

Thorsten Haas, MD  
Professor of Anaesthesiology  
Department of Paediatric Anaesthesia  
University Children's Hospital Zurich  
Steinwiesstrasse 75  
CH-8032 Zurich  
Switzerland  
E-Mail: thorsten.haas@kispi.uzh.ch  
*Chapter 6.*

Sibylle Kietzibl, MD, MBA  
Professor of Anaesthesiology  
Department of Anaesthesia and Intensive Care  
Evangelical Hospital Vienna  
Hans-Sachs-Gasse 10-12  
A-1180 Vienna  
Austria  
E-Mail: s.kietzibl@ekhwien.at  
*Chapter 1.*

Marcus D. Lancé  
Department of Anesthesiology and perioperative medicine  
Hamad Medical Corporation  
Doha  
Qatar  
*Chapter 9.*

Barto Nascimento  
Sunnybrook Health Sciences Centre  
2075 Bayview Ave., Room H1 71  
Toronto, ON, M4N 3M5  
Canada  
*Chapter 8.*

Vojislava Neskovic, MD, PhD, DEAA  
Military Medical Academy  
Belgrade  
Serbia

*Chapter 4.*

Marco Ranucci  
Department of Cardiothoracic Vascular Anesthesia and Intensive Care  
IRCCS Policlinico S. Donato  
Piazza Edmondo Malan, 2  
I-20097 San Donato Milanese  
Italy

*Chapter 3.*

PD Dr. Christoph J. Schlimp  
Department of Anaesthesiology & Intensive Care  
Evangelical Hospital Vienna  
Hans-Sachs-Gasse 10-12  
A-1180 Vienna  
Austria

*Chapter 7.*

Kenichi A. Tanaka, MD, MSc  
Department of Anesthesiology  
University of Maryland School of Medicine  
22 South Greene Street, Suite S8D12  
Baltimore, Maryland 21201  
U.S.A.  
Email: ktanaka@som.umaryland.edu

*Chapter 2.*

Anne Juul Wikkelsø, MD, PhD  
Department of anaesthesia and intensive care medicine  
Hvidovre Hospital  
Kettegård Alle 30  
DK-2650 Hvidovre  
Denmark

*Chapter 10.*



# Contents

<b>1.</b>	<b>Introduction</b>	<b>10</b>
<b>2.</b>	<b>Pathophysiology of Fibrinogen</b>	<b>12</b>
2.1.	Hereditary Fibrinogen Disorders.....	12
2.1.1.	Type I Fibrinogen Deficiency.....	12
2.1.2.	Type II Fibrinogen Deficiency.....	13
2.1.3.	Laboratory Testing and Treatments.....	13
2.2.	Genetic Polymorphisms and Altered Fibrin Structure.....	13
2.3.	Hyperfibrinogenaemia.....	14
2.4.	Disseminated Intravascular Coagulation.....	14
2.5.	Fibrinogen Disorders in Major Trauma.....	14
2.6.	Fibrinogen Disorders in Cardiovascular Surgery.....	16
2.7.	Fibrinogen Disorders in Liver Transplantation.....	17
2.8.	Fibrinogen Disorders in Obstetric Haemorrhage.....	18
2.9.	Summary and Perspectives.....	18
2.10.	References.....	19
<b>3.</b>	<b>Fibrinogen in Cardiac Surgery</b>	<b>24</b>
3.1.	Mechanisms of Fibrinogen Consumption during Cardiac Surgery.....	24
3.2.	The Association between Bleeding and Fibrinogen Levels.....	25
3.3.	Fibrinogen Supplementation in Cardiac Surgery.....	27
3.4.	Paediatric Setting.....	30
3.5.	Conclusion.....	30
3.6.	References.....	31
<b>4.</b>	<b>Fibrinogen and Other Factor Concentrates in Trauma Bleeding</b>	<b>33</b>
4.1.	Mechanism of Bleeding in Trauma – Setting the Scene.....	33
4.2.	Monitoring – or Why are Viscoelastic Tests Important.....	34
4.3.	Fibrinogen Concentrate – How and Why.....	35
4.4.	Timing for Fibrinogen – Sequence of Actions.....	38
4.5.	Is there an Indication for Prothrombin Complex Concentrate (PCC) in Trauma?.....	38
4.6.	PCC, New Oral Anticoagulant Agents (NOACs) and Trauma.....	39
4.7.	One Patient – More Than One Concentrated Factor: Both Fibrinogen and PCC.....	40
4.8.	Conclusion.....	41
4.9.	References.....	41
<b>5.</b>	<b>Fibrinogen and Peri-Partum Haemorrhage</b>	<b>45</b>
5.1.	Hypofibrinogenaemia is a Risk Marker of PPH Severity.....	46
5.2.	The Way to Correct Fibrinogen Plasma Level.....	47
5.3.	When Should Hypofibrinogenaemia Be Corrected?.....	50
5.4.	Which Fibrinogen Concentrate Dose Target to Stop Bleeding?.....	51
5.5.	Is Concomitant Inhibition of Fibrinolysis Indicated?.....	51
5.6.	When do We Need Drugs to Boost Thrombin Generation?.....	52
5.7.	Factor XIII in PPH Induced Coagulopathy.....	52
5.8.	Balanced Benefit Risk Regarding Side Effects and Economic Balance.....	54

5.9.	Who Should Correct Hypofibrinogenaemia? .....	54
5.10.	Conclusion .....	54
5.11.	References.....	54
<b>6.</b>	<b>Fibrinogen and Other Concentrates in Paediatric Patients</b>	<b>57</b>
6.1.	Fibrinogen Physiologic and Pathological Role in Haemostasis .....	57
6.2.	Fibrinogen Supplementation Modalities.....	58
6.3.	Fibrinogen Concentrate.....	58
6.4.	Prothrombin Complex Concentrate .....	59
6.5.	Factor XIII Concentrate.....	60
6.6.	Recombinant Activated Factor VII .....	60
6.7.	Antifibrinolytics.....	60
6.8.	References.....	61
<b>7.</b>	<b>Fibrinogen Replacement: Plasma, Cryoprecipitate, Concentrate</b>	<b>64</b>
7.1.	Available Sources for Fibrinogen Supplementation .....	64
7.2.	Use and Comparison of Plasma and Fibrinogen Concentrate .....	65
7.3.	Further Research, Experimental Studies and Outlook of Fibrinogen Supplementation .....	66
7.4.	Conclusion .....	66
7.5.	References.....	66
<b>8.</b>	<b>Factor Concentrates (Fibrinogen, PCC, FXIII) versus Cryoprecipitate</b>	<b>70</b>
8.1.	Cryoprecipitate .....	70
8.2.	Prothrombin Complex Concentrates .....	72
8.3.	Factor XIII.....	73
8.4.	Fibrinogen Concentrate.....	73
8.5.	Conclusion .....	74
8.6.	References.....	74
<b>9.</b>	<b>Factor Concentrates (Fibrinogen, PCC, FXIII) versus FFP in Patient Blood Management</b>	<b>77</b>
9.1.	Fresh Frozen Plasma .....	77
9.2.	Fibrinogen.....	80
9.3.	Prothrombin Complex Concentrate .....	82
9.4.	FXIII .....	83
9.5.	Conclusion .....	85
9.6.	References.....	85
<b>10.</b>	<b>Fibrinogen in the ESA Guidelines</b>	<b>91</b>
10.1.	An Introduction to the GRADE System .....	91
10.2.	Fibrinogen Recommendations of the ESA Guideline 2017 .....	94
10.3.	Randomized Controlled Trials Evaluating Fibrinogen Concentrate .....	94
10.4.	Bias Assessment of Randomized Controlled Trials .....	94
10.5.	Bias related to observational, non-randomized studies .....	99
10.6.	Conclusion .....	101
10.7.	References .....	101
	<b>Index</b>	<b>103</b>

# 1. Introduction

## What Can Be Expected in the Following Nine Book Chapters?

Hypofibrinogenaemia is the grey eminence behind all chapters. Normal ranges of fibrinogen levels and hypofibrinogenaemia have been defined; fibrinogen levels can be measured in blood samples.

In **Chapter 2**, K. Tanaka et al. describe easy to digest pathophysiology of bleeding. This chapter highlights differences between acquired and inherited hypofibrinogenaemia. When considering the pathophysiological role of fibrinogen as the polar star for clinical decision-making, it appears self-evident to correct acquired hypofibrinogenaemia in order to produce stronger clots, reduce blood loss, and allogeneic blood transfusion requirements.

Key message in **Chapter 3**, by M. Ranucci is fibrinogen replacement in acquired perioperative hypofibrinogenaemia < 1.5 g/L in cardiac surgery: when to replace, when not to replace, and how to replace fibrinogen. Noteworthy, cardiac surgical bleeding has been selected in recent international licensing trials of various companies manufacturing fibrinogen concentrates. Some were successful, some failed. This brilliant chapter may open our eyes for potential flaws in study designs, e.g., adequate timing and dosing or ignoring the prerequisite for replacement - which is hypofibrinogenaemia.

Time is life: In **Chapter 4**, Neskovic highlights the importance of speedy diagnostics and speedy therapy in the life-threatening situation of severe trauma-dependent bleeding. Fibrinogen can be depleted very early and fast in TIC. Fibrinogen is the usual suspect for timely substitution before other coagulation factors need replacement. Viscoelastic haemostatic assays (VHA) permit speedy diagnostics of the actual demand for fibrinogen replacement as well as fibrinogen-independent bleeding sources. This exciting chapter demonstrates the shift in bleeding management: from blind, not goal-directed, not individualized, allogeneic blood product-based bleeding management towards a targeted, coagulation factor concentrate-based approach with a restrictive

and transfusion trigger-based use of allogeneic blood products.

Hyperfibrinolysis is the common problem in TIC and PPH. Fibrin and fibrinogen are designed to be dissolved by plasmin-dependent fibrinogenolysis which is the basis for later (after-clotting) recanalisation of injured vessels, re-perfusion, and finally wound healing. Excessive lysis (hyperfibrinolysis), however, breaks down clots too early resulting in ongoing bleeding. Anti-fibrinolytic drugs are required to prevent fibrinogen consumption - before fibrinogen replacement.

**Chapter 5** is dedicated to PPH as a pathophysiological model of hyperfibrinolysis and defibrination. A. Ducloy-Bouthors and R. Collis in their chapter highlight the fact that normal ranges of fibrinogen are much higher upon delivery as well as the predictive value of hypofibrinogenaemia for the progression of PPH and for failure of balloon compression, requiring surgical escalations up to hysterectomy for bleeding control. For practical implementation this chapter offers a protocol for VHA-targeted fibrinogen replacement.

As simple as that: a) severe bleeding in our youngest population is an emotional clinical situation and b) critical low fibrinogen levels can accelerate bleeding in infants and children. In **Chapter 6**, S. Goobie and T. Haas describe crystal clear that fibrinogen is the first coagulation factor that achieves critical low levels. Although the Clauss assay is globally established to assess fibrinogen levels in the paediatric population, functional fibrinogen activity in VHA (specifically the FIBTEM measuring the fibrinogen contribution to clot strength) is assessed much faster, almost in real time. VHA has been shown to be effective in guiding paediatric perioperative bleeding management.

In **Chapter 7**, C. Schlimp describes current sources of fibrinogen for replacement: by transfusing plasma (FFP), cryoprecipitate or by infusing fibrinogen concentrate. Plasma and cryoprecipitate traditionally serve as the main sources of fibrinogen replacement worldwide despite poor evidence to support any benefit for the prophylactic or therapeutic use of these blood components to correct hypofibrinogenaemia.